Prostaglandin receptors EP2, EP3, and IP mediate exudate formation in carrageenin-induced mouse pleurisy.
The roles of prostaglandins (PGs) as mediators of inflammation have been extensively studied, and production of PGI2 and PGE2 at inflammatory sites has been reported. However, it has not yet been clarified which type of PG receptors has a major role in inflammatory exudation. To examine in vivo role of PG receptors in inflammatory exudation, we induced pleurisy in PG receptors (IP, EP1, EP2, EP3, or EP4) knockout mice by intrapleural injection of carrageenin. Pleural exudate accumulation in wild-type (WT) mice at 1 to 5 h, but not at 24 h, was significantly attenuated by the pretreatment with indomethacin, indicating that PGs are responsible for exudate formation at the early phase of pleurisy. Pleural exudation at 1 to 5 h in IP, EP2, or EP3 knockout mice, but not in EP1 and EP4 knockout, was significantly reduced compared with in WT mice. In the exudates, 6-keto-PGF1alpha and PGE2 were detected as the major PGs, each with its peak concentration at 3 h. In addition, involvement of bradykinin in the phenomenon was suggested by the fact that captopril, a kininase inhibitor, enhanced the exudate formation and increased the amount of 6-keto-PGF1alpha and PGE2 and that a bradykinin B2-receptor antagonist inhibited the exudate formation. In contrast, leukocyte migration into pleural cavity was not influenced by indomethacin-treatment nor by these receptor deficiencies. These results demonstrate participation of EP2 and EP3 along with IP in pleural exudate formation but not in leukocyte migration in carrageenin-induced mouse pleurisy.
Department of Pharmacology, Asahikawa Medical College, Japan.
Koh-ichi
K
Yuhki
Akinori
A
Ueno
Hiroaki
H
Naraba
Fumiaki
F
Kojima
Fumitaka
F
Ushikubi
Shuh
S
Narumiya
Sachiko
S
Oh-ishi
D000527:Alprostadil / Q000031:analogs & derivatives* / Q000378:metabolism; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001920:Bradykinin / Q000502:physiology; D002216:Captopril / Q000494:pharmacology; D002351:Carrageenan; D015232:Dinoprostone / Q000378:metabolism; D005122:Exudates and Transudates / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D007213:Indomethacin / Q000494:pharmacology; D007700:Kinetics; D051379:Mice; D018345:Mice, Knockout; D010998:Pleurisy / Q000139:chemically induced* / Q000378:metabolism; D011453:Prostaglandins / Q000378:metabolism; D011804:Quinolines / Q000494:pharmacology; D044006:Receptors, Epoprostenol / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D018078:Receptors, Prostaglandin E / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; C105311:FR 173657; D011453:Prostaglandins; D011804:Quinolines; D044006:Receptors, Epoprostenol; D018078:Receptors, Prostaglandin E; C033246:prostaglandin E3; D002351:Carrageenan; D002216:Captopril; D000527:Alprostadil; D015232:Dinoprostone; D001920:Bradykinin; D007213:Indomethacin